| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 6,125 | 6,400 | 10:10 | |
| 6,130 | 6,395 | 10:12 |
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 23.09. | Sensorion H1 Loss Widens On Higher Operating Expenses | ||
| 23.09. | Sensorion Reports 2026 Half-Year Results, Provides Corporate Update and Announces Availability of Half-Year Report | Clinical Trial Applications (CTAs) for SENS-601 (GJB2-GT), the Company's lead gene therapy program for GJB2-related hearing loss were filed in France and Canada, with Fast Track procedure granted... ► Artikel lesen | |
| 18.09. | Sensorion Announces Connection Details for its SENS-601 Program Day on September 22, 2026 | Regulatory News:
Sensorion (FR001401A9Z0 ALSEN) ("the Company"), a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent... ► Artikel lesen | |
| 16.09. | Sensorion Confidentially Submits Draft Registration Statement On Form F-1 To SEC | BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - Sensorion has confidentially submitted a draft registration statement on Form F-1 to the U.S. Securities and Exchange Commission. The submission is a preliminary... ► Artikel lesen | |
| 16.09. | Sensorion Announces Confidential Submission of Draft Registration Statement to the SEC for Potential U.S. Initial Public Offering | Regulatory News:
Sensorion (FR001401A9Z0 ALSEN) ("the Company") a pioneering clinical-stage biotechnology company focused on developing novel therapies to restore hearing and treat and prevent... ► Artikel lesen |
